Akari Therapeutics, Plc
https://www.akaritx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akari Therapeutics, Plc
Finance Watch: Big Money In Post-Data Follow-On Offerings
Public Company Edition: Insmed grossed $650m, Structure raised $476m and Merus brought in $400.2m after positive clinical trial results. But while CARGO raised $110m in a private placement and Day One sold a priority review voucher for $108m, Ikena, Takeda and others cut jobs.
Akari, Peak Bio Hatch Merger Plan To Survive Together
Deal snapshot: Akari, which has stayed afloat through small financings in recent years, and Peak Bio, after going public via the SPAC route in 2022, will merge as equals and then prioritize their pipeline.
Redefining Statistical Significance For Rare Disease Research
Biopharma Excellence recently convened three experts in the world of rare disease in a roundtable to discuss the emerging approaches to data collection when patient populations are very small. Their discussion has been summarized for In Vivo.
Pivotal Data Boost Omeros’ Stem Cell Transplant Product After FDA Delay
Promising pivotal data boost chances for Omeros’ narsoplimab to become a highly needed, first-to-market drug for the treatment of a deadly complication of stem cell transplants.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Celsus Therapeutics plc
- Morria Biopharmaceuticals, plc
- Volution Immuno Pharmaceuticals SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice